JP2019533019A5 - - Google Patents

Download PDF

Info

Publication number
JP2019533019A5
JP2019533019A5 JP2019542355A JP2019542355A JP2019533019A5 JP 2019533019 A5 JP2019533019 A5 JP 2019533019A5 JP 2019542355 A JP2019542355 A JP 2019542355A JP 2019542355 A JP2019542355 A JP 2019542355A JP 2019533019 A5 JP2019533019 A5 JP 2019533019A5
Authority
JP
Japan
Prior art keywords
medicament according
subject
compound
dose
biomarker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019542355A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019533019A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/057203 external-priority patent/WO2018075650A1/en
Publication of JP2019533019A publication Critical patent/JP2019533019A/ja
Publication of JP2019533019A5 publication Critical patent/JP2019533019A5/ja
Priority to JP2023157999A priority Critical patent/JP2024001055A/ja
Priority to JP2025079296A priority patent/JP2025122012A/ja
Pending legal-status Critical Current

Links

JP2019542355A 2016-10-18 2017-10-18 Thr−ベータアゴニストで肝臓障害又は脂質障害を治療する方法 Pending JP2019533019A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023157999A JP2024001055A (ja) 2016-10-18 2023-09-22 Thr-ベータアゴニストで肝臓障害又は脂質障害を治療する方法
JP2025079296A JP2025122012A (ja) 2016-10-18 2025-05-12 Thr-ベータアゴニストで肝臓障害又は脂質障害を治療する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662409833P 2016-10-18 2016-10-18
US62/409,833 2016-10-18
US201762516594P 2017-06-07 2017-06-07
US62/516,594 2017-06-07
PCT/US2017/057203 WO2018075650A1 (en) 2016-10-18 2017-10-18 Methods of treating liver disorders or lipid disorders with a thr-beta agonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023157999A Division JP2024001055A (ja) 2016-10-18 2023-09-22 Thr-ベータアゴニストで肝臓障害又は脂質障害を治療する方法

Publications (2)

Publication Number Publication Date
JP2019533019A JP2019533019A (ja) 2019-11-14
JP2019533019A5 true JP2019533019A5 (cg-RX-API-DMAC10.html) 2020-11-19

Family

ID=60480362

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019542355A Pending JP2019533019A (ja) 2016-10-18 2017-10-18 Thr−ベータアゴニストで肝臓障害又は脂質障害を治療する方法
JP2023157999A Pending JP2024001055A (ja) 2016-10-18 2023-09-22 Thr-ベータアゴニストで肝臓障害又は脂質障害を治療する方法
JP2025079296A Pending JP2025122012A (ja) 2016-10-18 2025-05-12 Thr-ベータアゴニストで肝臓障害又は脂質障害を治療する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023157999A Pending JP2024001055A (ja) 2016-10-18 2023-09-22 Thr-ベータアゴニストで肝臓障害又は脂質障害を治療する方法
JP2025079296A Pending JP2025122012A (ja) 2016-10-18 2025-05-12 Thr-ベータアゴニストで肝臓障害又は脂質障害を治療する方法

Country Status (12)

Country Link
US (3) US11090308B2 (cg-RX-API-DMAC10.html)
EP (2) EP3528817B1 (cg-RX-API-DMAC10.html)
JP (3) JP2019533019A (cg-RX-API-DMAC10.html)
KR (2) KR20230156159A (cg-RX-API-DMAC10.html)
CN (1) CN110167557A (cg-RX-API-DMAC10.html)
AU (1) AU2017346871B2 (cg-RX-API-DMAC10.html)
CA (1) CA3040888A1 (cg-RX-API-DMAC10.html)
DK (1) DK3528817T3 (cg-RX-API-DMAC10.html)
ES (1) ES2924257T3 (cg-RX-API-DMAC10.html)
IL (2) IL302336B2 (cg-RX-API-DMAC10.html)
MX (1) MX394463B (cg-RX-API-DMAC10.html)
WO (1) WO2018075650A1 (cg-RX-API-DMAC10.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2795450T3 (es) 2012-09-17 2020-11-23 Madrigal Pharmaceuticals Inc Procedimiento para sintetizar análogos de hormonas tiroideas y polimorfos de los mismos
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
NZ748641A (en) 2016-06-13 2020-04-24 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
MX394463B (es) 2016-10-18 2025-03-19 Madrigal Pharmaceuticals Inc Métodos para tratar trastornos del hígado o trastornos lipídicos con un agonista de thr-beta.
ES2982801T3 (es) 2017-03-28 2024-10-17 Gilead Sciences Inc Combinaciones terapéuticas para el tratamiento de las enfermedades hepáticas
ES3029158T3 (en) * 2018-06-12 2025-06-23 Xizang Haisco Pharmaceutical Co Ltd Thyroid hormone receptor agonists and uses thereof
US20210292304A1 (en) * 2018-06-22 2021-09-23 Hinova Pharmaceuticals Inc. Deuterated mgl-3196 compound and use thereof
TW202615431A (zh) * 2018-07-02 2026-04-16 美商瑪德瑞高製藥公司 2-(3,5-二氯-4-((5-異丙基-6-側氧基-1,6-二氫噠嗪-3-基)氧)苯基)-3,5-二側氧基-2,3,4,5-四氫-1,2,4-三嗪-6-腈之固體型式
CA3111025C (en) 2018-09-06 2023-10-31 Galmed Research And Development Ltd Combination therapy for the treatment of liver disease
TWI884745B (zh) 2018-10-12 2025-05-21 美商拓臻股份有限公司 甲狀腺素受體β促效劑化合物
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
KR102692309B1 (ko) * 2019-01-15 2024-08-07 길리애드 사이언시즈, 인코포레이티드 Fxr (nr1h4) 조정 화합물
WO2020172075A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists
CN119431265A (zh) 2019-02-21 2025-02-14 南京瑞捷医药科技有限公司 一种作为甲状腺激素受体激动剂的化合物
WO2020227549A1 (en) 2019-05-08 2020-11-12 Aligos Therapeutics, Inc. MODULATORS OF THR-β AND METHODS OF USE THEREOF
CA3154488A1 (en) 2019-08-23 2021-03-04 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CA3154391A1 (en) * 2019-09-12 2021-03-18 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
WO2021063367A1 (zh) * 2019-09-30 2021-04-08 苏州科睿思制药有限公司 一种Resmetirom晶型及其制备方法和用途
CA3158379A1 (en) * 2019-11-26 2021-06-03 Hejun Lv 1,2,4-triazine-3,5-dione compound, preparation method therefor, and application thereof
CN111562321B (zh) * 2020-04-16 2022-10-28 广东省结核病控制中心 用于检测活动性肺结核的粪便代谢物及其检测系统
KR20230066408A (ko) * 2020-09-10 2023-05-15 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. 레스메티롬의 결정형, 이의 제조 방법 및 이의 용도
US12616701B2 (en) 2020-10-19 2026-05-05 Assia Chemical Industries Ltd Solid state forms of Resmetirom
WO2022165227A1 (en) * 2021-02-01 2022-08-04 Madrigal Pharmaceuticals, Inc. Therapeutic combinations of rosuvastatin and resmetirom for the treatment of liver disorders or lipid disorders
US20250000836A1 (en) * 2021-07-21 2025-01-02 Cyta Therapeutics, Inc. Particle delivery of thyroid hormone receptor agonists and antagonists
TW202337470A (zh) 2021-09-27 2023-10-01 美商瑪德瑞高製藥公司 用於縮減肝臟體積之瑞美替隆
MX2024005647A (es) * 2021-11-11 2024-05-24 Terns Pharmaceuticals Inc Tratamiento de trastornos hepaticos con un agonista del thr-\03b2.
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
JP2026521649A (ja) * 2023-06-22 2026-06-30 マドリガル ファーマシューティカルズ インコーポレイテッド THR-βアゴニストを用いて肝障害を治療するためのバイオマーカーおよび関連する使用
WO2025011259A1 (zh) * 2023-07-07 2025-01-16 苏州科睿思制药有限公司 瑞司美替罗的晶型及其制备方法和用途
EP4762048A2 (en) 2023-10-16 2026-06-24 Cipla Limited Resmetirom polymorphs and process for their preparation
US12377104B1 (en) 2024-02-06 2025-08-05 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease
WO2025245216A1 (en) * 2024-05-22 2025-11-27 Terns Pharmaceuticals, Inc. Treatment of liver disorders with a thr-beta agonist
WO2026074443A1 (en) 2024-10-01 2026-04-09 Assia Chemical Industries Ltd. Solid state forms of resmetirom
CN121648128B (zh) * 2026-02-03 2026-06-30 华中科技大学同济医学院附属同济医院 特拉唑嗪或其药学上可接受的盐在制备用于预防和/或治疗肝纤维化的药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5615272A (en) 1979-07-17 1981-02-14 Ishihara Sangyo Kaisha Ltd N-benzoyl-n'-phenylurea compound, its preparation, and insecticide containing the same
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
WO2004085406A1 (en) 2003-03-24 2004-10-07 F. Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
ITRM20030363A1 (it) 2003-07-24 2005-01-25 Fernando Goglia Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
US7807647B2 (en) 2004-06-01 2010-10-05 Pronai Therapeutics, Inc. Methods and compositions for cancer therapy
US20050287667A1 (en) 2004-06-01 2005-12-29 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
ATE480524T1 (de) 2005-07-21 2010-09-15 Hoffmann La Roche Pyridazinonderivate als schilddrüsenhormon- rezeptoragonisten
ES2351274T3 (es) 2007-06-06 2011-02-02 Torrent Pharmaceuticals Ltd Nuevos compuestos.
US8076334B2 (en) 2007-09-20 2011-12-13 Hoffmann-La Roche Inc. Prodrugs of thyroid hormone analogs
ES2795450T3 (es) 2012-09-17 2020-11-23 Madrigal Pharmaceuticals Inc Procedimiento para sintetizar análogos de hormonas tiroideas y polimorfos de los mismos
US8858502B2 (en) 2012-10-10 2014-10-14 Alcon Research, Ltd. Systems and methods for external pressure sensing
WO2015123256A1 (en) * 2014-02-14 2015-08-20 Cempra Pharmaceuticals, Inc. Compositions and methods for treating diabetes and liver diseases
MX394463B (es) 2016-10-18 2025-03-19 Madrigal Pharmaceuticals Inc Métodos para tratar trastornos del hígado o trastornos lipídicos con un agonista de thr-beta.
TW202615431A (zh) 2018-07-02 2026-04-16 美商瑪德瑞高製藥公司 2-(3,5-二氯-4-((5-異丙基-6-側氧基-1,6-二氫噠嗪-3-基)氧)苯基)-3,5-二側氧基-2,3,4,5-四氫-1,2,4-三嗪-6-腈之固體型式

Similar Documents

Publication Publication Date Title
US11806353B2 (en) Methods of treating liver disorders or lipid disorders with a THR-beta agonist
Flanagan et al. Activation of 5-HT2 receptors reduces inflammation in vascular tissue and cholesterol levels in high-fat diet-fed apolipoprotein E knockout mice
Zhou et al. Adipose‐specific lipin‐1 overexpression renders hepatic ferroptosis and exacerbates alcoholic steatohepatitis in mice
Tosco et al. A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR
Ni et al. USP7 mediates pathological hepatic de novo lipogenesis through promoting stabilization and transcription of ZNF638
Disatnik et al. Potential biomarkers to follow the progression and treatment response of Huntington’s disease
Zhang et al. STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma
Wang et al. Serotonin transporter gene promoter region polymorphisms and serotonin transporter expression in the colonic mucosa of irritable bowel syndrome patients
Hwangbo et al. Prevalence and clinical characteristics of recently diagnosed type 2 diabetes patients with positive anti-glutamic acid decarboxylase antibody
US20160178584A1 (en) Methods for diagnosing and assessing kidney disease
Ellis et al. Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism
Ferreira‐Marques et al. Ghrelin delays premature aging in Hutchinson‐Gilford progeria syndrome
Masek-Hammerman et al. Monoclonal antibody against macrophage colony-stimulating factor suppresses circulating monocytes and tissue macrophage function but does not alter cell infiltration/activation in cutaneous lesions or clinical outcomes in patients with cutaneous lupus erythematosus
AU2022267325A1 (en) Methods for treating and monitoring parkinson's disease
Han et al. Circulating glutamine/glutamate ratio is closely associated with type 2 diabetes and its associated complications
Li et al. Ube2L6 promotes M1 macrophage polarization in high-fat diet-fed obese mice via ISGylation of STAT1 to trigger STAT1 activation
EP2640372A1 (en) Preselection of subjects for therapeutic treatment with elesclomol based on hypoxic status
Dagli-Hernandez et al. Late response to rosuvastatin and statin-related myalgia due to SLCO1B1, SLCO1B3, ABCB11, and CYP3A5 variants in a patient with Familial Hypercholesterolemia: a case report
Xu et al. Cranial irradiation induces hypothalamic injury and late-onset metabolic disturbances in juvenile female rats
Zhang et al. IL-17 enhanced the susceptibility to fluoxetine resistance in depression via the JAK1-STAT6 signaling pathway
Vinagre et al. Differentiated thyroid cancer in patients with resistance to thyroid hormone syndrome. A novel case and a review of the literature
CN118252935A (zh) Trafd1抑制剂在制备治疗和/或预防hbv-ra药物中的应用
Xing et al. BRAFV600E mutation contributes papillary thyroid carcinoma and Hashimoto thyroiditis with resistance to thyroid hormone: A case report and literature review
Al‐Bataineh et al. Tumor necrosis factor alpha increases P‐glycoprotein expression in a BME‐UV in vitro model of mammary epithelial cells
Potaczek et al. The I allele of the angiotensin-converting enzyme gene polymorphism may determine an increase in homocysteine levels in fibrate-treated subjects